PPA
NVCR icon

Parametric Portfolio Associates’s NovoCure NVCR Stock Holding History

Parametric Portfolio Associates’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$17.8M Buy
215,042
+90,520
+73% +$6.67M 0.01% 1026
2021
Q4 		$9.35M Buy
124,522
+36,311
+41% +$3.64M ﹤0.01% 1438
2021
Q3 		$10.2M Sell
88,211
-14,058
-14% -$2.13M 0.01% 1339
2021
Q2 		$22.7M Buy
102,269
+33,950
+50% +$6.6M 0.01% 896
2021
Q1 		$9.03M Buy
68,319
+14,727
+27% +$2.33M 0.01% 1753
2020
Q4 		$9.27M Sell
53,592
-945
-2% -$129K 0.01% 1628
2020
Q3 		$6.07M Sell
54,537
-4,009
-7% -$321K ﹤0.01% 1745
2020
Q2 		$3.47M Sell
58,546
-11,346
-16% -$746K ﹤0.01% 2125
2020
Q1 		$4.71M Sell
69,892
-2,843
-4% -$225K ﹤0.01% 1774
2019
Q4 		$6.13M Sell
72,735
-15,628
-18% -$1.26M ﹤0.01% 1896
2019
Q3 		$6.61M Buy
88,363
+24,929
+39% +$1.99M 0.01% 1802
2019
Q2 		$4.01M Sell
63,434
-5,399
-8% -$274K ﹤0.01% 2167
2019
Q1 		$3.32M Sell
68,833
-5,583
-8% -$269K ﹤0.01% 2289
2018
Q4 		$2.49M Sell
74,416
-16,992
-19% -$621K ﹤0.01% 2434
2018
Q3 		$4.79M Sell
91,408
-22,864
-20% -$910K ﹤0.01% 2052
2018
Q2 		$3.58M Buy
114,272
+47,886
+72% +$1.33M ﹤0.01% 2236
2018
Q1 		$1.45M Sell
66,386
-33,542
-34% -$721K ﹤0.01% 2803
2017
Q4 		$2.02M Buy
99,928
+58,074
+139% +$1.12M ﹤0.01% 2598
2017
Q3 		$831K Buy
41,854
+24,165
+137% +$475K ﹤0.01% 3139
2017
Q2 		$306K Buy
+17,689
New +$228K ﹤0.01% 3624

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's NVCR Position: Q1 2022 in Review

Parametric Portfolio Associates increased its NovoCure (NVCR) stake by 73% in Q1 2022, buying an estimated $6.67M and bringing the position to 215,042 shares worth $17.8M. The position accounts for 0.01% of the portfolio, ranked #1026.

Parametric Portfolio Associates first reported a position in NVCR in Q2 2017 and has held it in 20 quarters since. The position peaked at $22.7M in Q2 2021. 309 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

  • Parametric Portfolio Associates held 215,042 shares of NovoCure worth $17.8M as of Q1 2022.
  • Parametric Portfolio Associates bought 90,520 NovoCure shares in Q1 2022, an estimated $6.67M.
  • NovoCure made up 0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1026 holding.
  • Parametric Portfolio Associates first reported a position in NovoCure in Q2 2017 and has held it in 20 quarters since.
  • Parametric Portfolio Associates's NovoCure position peaked at $22.7M in Q2 2021.
  • 309 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.